Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486065 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT05486065 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 245 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05486065, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
California
- Velocity Clinical Res-Banning - Banning
- Velocity Clin Res-Chula Vista - Chula Vista
- Southern California Res Ctr - Coronado
- Cedars-Sinai Medical Group - Encino
- Velocity Clin Res Gardena - Gardena
- Nat Res Inst Huntington Park - Huntington Park
- Scripps Whittier Diabetes Inst - La Jolla
- First Valley Med Grp Lancaster - Lancaster
- Velocity Clin Res Los Angeles - Los Angeles
- Diabetes Assoc. Med Group - Orange
- Western University of Health Sciences - Pomona
- San Diego Family Care_San Diego - San Diego
- Mills-Peninsula Hlth Services - San Mateo
- Encompass Clinical Research_Spring Valley - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Alabama
- Univ of Alabama Birmingham - Birmingham
- University of Alabama Birmingham - Birmingham
Florida
- Innovative Research of W FL - Clearwater
- Tampa Bay Medical Research - Clearwater
Colorado
- Optumcare Clinical Trials,LLC-Golden - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05486065
The ClinicalTrials.gov registry entry for NCT05486065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05486065 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT05486065 about?
NCT05486065 is a clinical study titled "A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight". This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at differe...
What is the current status of trial NCT05486065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2022-08-08. Estimated completion is 2023-12-13.
What conditions does trial NCT05486065 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05486065?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05486065?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486065 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.